Skip to content

Analysis of Efficacy and Safety of Different Antimicrobial Agents in Treating Pseudomonas aeruginosa Infections: A Single-Centre Retrospective Cohort Study

Analysis of Efficacy and Safety of Different Antimicrobial Agents in Treating Pseudomonas aeruginosa Infections: A Single-Centre Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118036
Enrollment
Unknown
Registered
2026-02-01
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas aeruginosa infection

Interventions

Observation group treated with different antibacterial drugs:None

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Ceftazidime-tazobactam, polymyxin, ceftazidime-avibactam, imipenem-cilastatin-relibactam, meropenem-ferbortan or amikacin-avibactam for cases treated for more than 3 days

Exclusion criteria

Exclusion criteria: 1.The medication has not been taken for more than three days. 2.Incomplete case information;

Design outcomes

Primary

MeasureTime frame
Infection indicators (white blood cells, neutrophil percentage, C- reactive protein, procalcitonin, erythrocyte sedimentation rate, etc.);

Secondary

MeasureTime frame
Biochemical indicators (transaminase, bilirubin, albumin, creatinine, urea, creatinine clearance rate, etc.);

Countries

China

Contacts

Public ContactJian Liu

The First Affiliated Hospital of Nanchang University

812347602@qq.com+86 791 8869 2482

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026